For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Erenumab - Migraine (prevention)
PAD Profile : Erenumab - Migraine (prevention)
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Pizotifen malate
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands Area Prescribing Committee agreed to adopt the South West London (SWL) migraine prophylaxis drug pathway for chronic and episodic migraine.
NOTE: updates and new additions to the pathway are provided in addendums at the end of the document.
See the Migraine (prophylaxis) Drug Pathway for full information.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the use of erenumab as a treatment option for preventing migraine in line with NICE TA682.
Erenumab will be given a RED traffic light status for this indication
Erenumab is a payment by results drug and blueteq forms for initiation and continuation will be available for specialist teams to complete.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication